Evidence map›Paper›PMID 36713553›Full record

ArticleFrontiers in oncology2022

Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer.

Yiming Chang, Zhiyuan Huang, Hong Quan, Hui Li, Shuo Yang, Yifei Song, Jian Wang, Jian Yuan, Chenming Wu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yiming ChangJinzhou Medical University, Shanghai East Hospital, Shanghai, China.
Zhiyuan HuangResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Hong QuanDepartment of Breast Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Hui LiDepartment of Gynaecology and Obstetrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Shuo YangDepartment of Medical Imaging, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yifei SongDepartment of Biochemistry and Molecular Biology, Tongji University School of Medicine, Shanghai, China.
Jian WangDepartment of Pharmacy, Shanghai Pudong New Area People's Hospital, Shanghai, China.
Jian YuanResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Chenming WuResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Shanghai East Hospital · CNJinzhou Medical University · CNPudong New Area People's Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA damage repair (DDR) genes are involved in developing breast cancer. Recently, a targeted therapeutic strategy through DNA repair machinery, including PARPi, has initially shown broad development and application prospects in breast cancer therapy. However, few studies that focused on the correlation between the expression level of DNA repair genes, prognosis, and immune response in breast cancer patients have been recently conducted. Herein, we focused on identifying differentially expressed DNA repair genes (DEGs) in breast cancer specimens and normal samples using the Wilcoxon rank-sum test. Biofunction enrichment analysis was performed with DEGs using the R software "cluster Profiler" package. DNA repair genes were involved in multivariate and univariate Cox regression analyses. After the optimization by AIC value, 11 DNA repair genes were sorted as prognostic DNA repair genes for breast cancer patients to calculate risk scores. Simultaneously, a nomogram was used to represent the prognostic model, which was validated using a calibration curve and C-index. Single-sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithms, and ESTIMATE scores were applied to evaluate the immune filtration of tumor samples. Subsequently, anticarcinogen sensitivity analysis was performed using the R software "pRRophetic" package. Unsupervised clustering was used to excavate the correlation between the expression level of prognostic-significant DNA repair genes and clinical features. In summary, 56 DEGs were sorted, and their potential enriched biofunction pathways were revealed. In total, 11 DNA repair genes (

Indexed as

breast cancerDNA damage repairimmune filtrationimmune responseprognostic model

Identifiers

PMID36713553
PMCPMC9875088
OpenAlexW4315650520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.